# Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

> **NCT03318445** · PHASE1 · COMPLETED · sponsor: **Pamela Munster** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor, Unspecified, Adult

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03318445
- **Lead sponsor:** Pamela Munster
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-12
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318445, "Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03318445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*